Full-Time
Biotech immunology company developing therapeutic antibodies
$156k - $214.5k/yr
Boston, MA, USA
Hybrid
Hybrid role; on-site days in Boston, MA required.
Bachelor's, Master's
See people who can refer or advise you
argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Ghent, Belgium
Founded
2008
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
argenx reported positive Phase 3 results for its ALKIVIA trial evaluating VYVGART Hytrulo in adults with autoimmune myositis. The trial met its primary endpoint, with patients showing statistically significant improvements in Total Improvement Score over 52 weeks versus placebo. The study marks the first Phase 3 trial demonstrating benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies. The safety profile remained consistent with prior studies. The company recently received US FDA priority review for VYVGART in seronegative generalized myasthenia gravis, with a decision expected on 10 May 2026. These label expansions could broaden VYVGART's reach across multiple autoimmune conditions. argenx's shares rose 11.5% following the announcement. The company's narrative projects $9.7 billion revenue and $3.5 billion earnings by 2029, requiring 22.3% yearly revenue growth.
argenx, a commercial-stage biopharma company specialising in autoimmune disease treatments, has attracted investor attention following recent share price movements. The stock closed at €767, up approximately 6% over the past week and 38.6% over the past year, bringing its market value to around €47.97 billion. The company generates revenue of €5.3 billion, primarily from its VYVGART franchise, with operations spanning the United States, Japan, China, and other markets. According to a widely followed valuation narrative, argenx appears 11.7% overvalued, with a fair value estimate of €686.43. The analysis credits the company's leadership in FcRn inhibitors and strong commercial growth, whilst noting typical biotech risks including single-asset dependence and pricing pressure. Revenue has doubled over two years, supporting the growth thesis.
argenx signs new strategic partnership agreement with Monash-originated biotechnology company Myostellar. * Education * 6 Aug 2026 8:33 am AEST * Share Monash University Global immunology company argenx has entered into a new strategic partnership agreement with Monash University and Monash-originated spinout Myostellar, to develop novel first in class molecules for muscular therapeutic areas. This new agreement builds on the existing strategic research and innovation partnership between Monash and argenx from earlier this year and demonstrates both organisations' commitment to advancing novel scientific research in the interest of patients. In 2022 Myostellar received $500,000 through the inaugural funding round of Brandon Biocatalyst's CUREator program, Australia's national biotechnology incubator, to support the development of regenerative therapies for muscular dystrophies, alongside investment from Monash Investment Holdings. In 2025, it was one of the inaugural recipients of the Monash Ventures Pre-Seed Fund, a $15 million initiative developed by Monash University in partnership with Breakthrough Victoria. Myostellar continues to be governed by Monash Investment Holdings nominee directors Dr Alison Greenway, Associate Dean and Senior Director, Enterprise and Partnerships, MNHS, and Dr Callum Benson, Investment Director, Monash Ventures. argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. The company has a long-standing history and track record of partnering with leading academic and clinical researchers through its Immunology Innovation Program (IIP) to translate scientific breakthroughs into a portfolio of novel antibody-based medicines. Professor Currie and Professor Martino said: "As researchers, our goal has always been to see our discoveries create meaningful impact for patients. We're proud to be partnering with argenx to help realise that ambition with the support of Monash's business and commercialisation teams." Dr Andrea Huggins, Vice-President (Innovation and Commercialisation), said: "It's outstanding to see Myostellar's trajectory from company formation to early-stage investment and global industry partnership, informed by Monash's commercialisation talent and capabilities." Dr Greenway said: "This research collaboration agreement with argenx represents a powerful endorsement of the depth of expertise, capability and globally recognised talent across medicine and health sciences at Monash." City & Local Guides Kathryn Evans, General Manager, Australia at argenx, said: "National Tribune is very pleased to further strengthen argenx's relationship with Monash through the new research collaboration, enabling National Tribune to access and deeply engage with Australia's world-class research community. "Built on transparency, long-term commitment, and shared success, our Immunology Innovation Program reflects how argenx works best - side-by-side with collaborators, advancing science that has the potential to define what's possible for patients. We look forward to working with Monash and Myostellar and bringing together their scientific expertise with argenx's global development capabilities." The agreement builds on the strategic research and innovation partnership between Monash and argenx announced in January 2026. The earlier partnership brought together Monash research expertise and argenx's development capabilities to advance an antibody molecule in preclinical development. Discover more City & Local Guides Southeast Asians & Pacific Islanders
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction argenx (Euronext Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth